Interferon free therapy with direct acting antivirals for HCV

Genomics and HCV infection: Progression of fibrosis and treatment response

(2012) Emilie Estrabaud et al.   JOURNAL OF HEPATOLOGY

A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication

(2012) Tarik Asselah   JOURNAL OF HEPATOLOGY

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The NS5A Replication Complex Inhibitors: Difference Makers?

(2011) Robert G. Gish et al.   Clinics in Liver Disease

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

(2011) Stefan Zeuzem et al.   GASTROENTEROLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C

(2010) Tarik Asselah   JOURNAL OF HEPATOLOGY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

(2009) Michelle Martinot-Peignoux et al.   HEPATOLOGY

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C

(2008) Sarah Maylin et al.   GASTROENTEROLOGY